Evidence map›Paper›PMID 35978866›Full record

ReviewWorld journal of gastroenterology2022

Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center.

Thais Maloberti, Antonio De Leo, Viviana Sanza, Elisa Gruppioni, Annalisa Altimari, Mattia Riefolo, Michela Visani, Deborah Malvi, Antonia D'Errico, Giovanni Tallini and 2 more

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Thais MalobertiDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40138, Italy.
Antonio De LeoDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40138, Italy.
Viviana SanzaSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Elisa GruppioniSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Annalisa AltimariSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Mattia RiefoloDepartment of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Michela VisaniDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40138, Italy.
Deborah MalviDepartment of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Antonia D'ErricoDepartment of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Giovanni TalliniDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40138, Italy.
Francesco VasuriDepartment of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Dario de BiaseDepartment of Pharmacy and biotechnology (FaBiT), University of Bologna, Bologna 40138, Italy. dario.debiase@unibo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) represents the primary carcinoma of the liver and the fourth leading cause of cancer-related deaths. The World Health Organization estimates an increase in cases in the coming years. The risk factors of HCC are multiple, and the incidence in different countries is closely related to the different risk factors to which the population is exposed. The molecular mechanisms that drive HCC tumorigenesis are extremely complex, but understanding this multistep process is essential for the identification of diagnostic, prognostic, and therapeutic markers. The development of multigenic next-generation sequencing panels through the parallel analysis of multiple markers can provide a landscape of the genomic status of the tumor. Considering the literature and our preliminary data based on 36 HCCs, the most frequently altered genes in HCCs are

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHigh-Throughput Nucleotide SequencingHumansMutationCTNNB1HepatocarcinomaMutationNext-generation sequencingReviewTERTTP53

Identifiers

PMID35978866
PMCPMC9280731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.